Complete hematologic and cytogenetic response to 2-amino-9-β-D- arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogeneous leukemia in T-cell blastic phase: A case report and review of the literature

Cancer

Volumn 85, Issue 1, 1999, Pages 58-64

  Aguayo, Alvaro ^a   Cortes, Jorge E ^a   Kantarjian, Hagop M ^a   Beran, Miloslav ^a   Gandhi, Varsha ^a   Plunkett, William ^a   Kurtzberg, Joanne ^b   Keating, Michael J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

2 amino 9 D arabinosyl 6 methoxy 9H guanine; Arabinosylguanine; Chronic myelogenous leukemia; Compound 506; T cell blastic phase

Indexed keywords

2 AMINO 9 BETA DEXTRO ARABINOSYL 6 METHOXY 9H GUANINE; CD19 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; GUANINE ARABINOSIDE; NELARABINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOGENETICS; DISEASE SEVERITY; HUMAN; MALE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; T LYMPHOBLAST; VIRUS CELL TRANSFORMATION;

ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; ARABINONUCLEOTIDES; BLAST CRISIS; GUANOSINE TRIPHOSPHATE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; REMISSION INDUCTION; T-LYMPHOCYTES;

EID: 0032919445     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990101)85:1<58::AID-CNCR8>3.0.CO;2-E     Document Type: Article

References (40)

1. Kantarjian HM, Deisseroth A, Kurzorck R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993;82:691-703.
2. Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med 1996;100:555-70.
3. Derderian PM, Kantarjian HM, Talpaz M, O'Brien S, Cork A, Estey E, et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 1993;94:69-74.
4. Herrman F, Ludwig WD, Kolecki P. Blast crisis in CML showing early T-lymphoblastic transformation. Br J Haematol 1984;56:175-6.
5. 1-positive chronic myeloid leukaemia blast crisis. Br J Haematol 1986;62:777-9.
6. Hernandez P, Carnot J, Cruz C. Chronic myeloid leukaemia blast crisis with T-cell features. Br J Haematol 1982; 51:175-80
7. 1-positive T lymphoblastic transformation of chronic granulocytic leukaemia in a lymph node. Lancet 1982;6:1053.
8. Griffin JD, Tantranahi R, Canellos GP, Wisch JS, Reinherz EL, Sherwood G, et al. T-cell surface antigens in a patient with blast crisis of chronic myeloid leukemia. Blood 1983;61: 640-4
9. Taniguchi C, Yamaguchi K, Yoshikoa R, Takifuji N, Matsui K, Nishimura H, et al. Blast crisis of chronic myelogenous leukemia with tumor formation characterized by T-cell features: a case report. Jpn J Clin Oncol 1984;14:123-7.
10. 1-positive T lymphoblastic transformation. Leuk Res 1984;8:737-9.
11. 1 positive blast crisis of chronic myeloid leukaemia exhibiting features characteristic of early T blasts. Scan J Haematol 1984;32:411-6.
12. 1-positive chronic myelogenous leukemia: Possible involvement of immature T lymphocytes. Cancer Genet Cytogenet 1985;15:119-27.
13. Soda H, Kuriyama K, Tomonaga M, Yao E, Amenomori T, Yoshida Y, et al. Lymphoid crisis with T-cell phenotypes in a patient with Philadelphia chromosome negative chronic myeloid leukaemia. Br J Haematol 1985;59:671-9.
14. Allouche M, Bourinbaiar A, Georgoulias V, Consolini R, Salvatore A, Auclair H, et al. T cell lineage involvement in lymphoid blast crisis of chronic myeloid leukemia. Blood 1985;66:1155-61.
15. Bartram CR, Janssen JWG, Becher R, De Klein A, Grosveld G. Persistence of chronic myelocytic leukemia despite deletion of rearranged bcr/c-abl sequences in blast crisis. J Exp Med 1986;164:1389-96.
16. Chan LC, Furley AJ, Ford AM, Yardumain DA, Greaves MF. Clonal rearrangement and expression of the T cell receptor β gene and involvement of the breakpoint cluster region in blast crisis of CGL. Blood 1986;67:533-6.
17. Fermand JP, Sigaux F, Tsapis A, Mathieu-Mahul D, Schmidtt C, Daniel MT, et al. T cell-derived blast crisis in chronic myelocytic leukemia. Leukemia 1987;1:210-2.
18. Yasukawa M, Iwamasa K, Kawamura S, Murakami S, Takada K, Hato T, et al. Phenotypic and genotypic analysis of chronic myelogenous leukaemia with T lymphoblastic and megakaryoblastic mixed crisis. Br J Haematol 1987;66:331-6.
19. Gramatzki M, Bartram CR, Muller D, Walter M, Tittelbach H, Kalden JR. Early T cell differentiated chronic myeloid leukemia blast crisis with rearrangement of the breakpoint cluster region but not of the T cell receptor B chain genes. Blood 1987;69:1082-6.
20. Kuriyama K, Gale RP, Tomonaga M, Ikeda S, Yao E, Klisak I. CML-T1: a cell line derived from T-lymphocyte acute phase of chronic myelogenous leukemia. Blood 1989;74:1381-7.
21. Advani SH, Malhotra H, Kadam PR, Lyer RS, Nanjangud G, Balsara B, et al. T-lymphoid blast crisis in chronic myeloid leukemia. Am J Hematol 1991;36:86-92.
22. Kawano K, Uno H, Ishizaki J, Matsuoka H, Komura K, Ishikawa T, et al. A case of adult T-cell leukemia with a defective HTLV-1 proviral DNA, in which the single T-cell clone appeared to have progressed from chronic phase to crisis. Jpn J Clin Hematol 1991;32:777-81
23. Matsushita K, Arima N, Fukumori J, Daitoku Y, Hidaka S, Ohtsubo H, et al. Ph1 positive myeloblastic crisis followed by Ph1 negative, bcr rearrangement positive T lymphoid crisis in a CML. Jpn J Clin Hematol 1993;34:348-54.
24. Konaka Y, Namiuchi S. Extramedullary blast crisis of mixed precursor T lymphoblastic and myeloblastic features in a patient with chronic myelogenous leukemia successfully treated with low dose oral etoposide. Jpn J Clin Hematol 1993;34:1556-61.
25. Watanabe T, Kataoka T, Mizuta S, Kobayashi M, Uchida T, Imai K, et al. Establishment and characterization of a novel cell line, TK-6, derived from T cell blast crisis of chronic myelogenous leukemia, with the secretion of parathyroid hormone-related protein. Leukemia 1995;9:1926-34.
26. Dorfman DM, Lontine JA, Fox EA, Weinberg DS, Pinkus GS. T-cell blast crisis in chronic myelogenous leukemia. Immunophenotypic and molecular biologic findings. Am J Clin Pathol 1997;107:168-76.
27. Copeland EA, McGuire E. The biology and treatment of acute lymphoid leukemia in adults. Blood 1995;85:1151-68.
28. Cohen A, Lee JWW, Gelfand EW. Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood 1983;61:660-6.
29. Shewach DS, Daddona PE, Ashcraft E, Mitchell BS. Metabolism and selective cytotoxicity of 9-β-D-arabinofuranosylguanine in human lymphoblasts. Cancer Res 1985;45:1008-14.
30. Ullman B, Martin DW. Specific cytotoxicity of arabinosylguanine toward cultures T lymphoblasts. J Clin Invest 1984; 74:951-5.
31. Shewach DS, Mitchell BS. Differential Metabolism of 9-β-D-arabinofuranosylguanine in human leukemic cells. Cancer Res 1989;49:6498-502.
32. Verhoef V, Fridland A. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. Cancer Res 1985;45:3646-50.
33. Hebert ME, Greenberg ML, Chaffee S, Gravatt L, Hershfield MS, Elion GB, et al. Pharmacologic purging of malignant T cells from human bone marrow using 9-B-D-arabinofuranosylguanine. Transplantation 1991;52:634-40.
34. Plunkett W, Gandhi V, Nowak B, Du M, Rodriguez CO, Keating MJ. Pharmacokinetics of compound 506, a soluble prodrug of arabinosylguanine, in adult leukemias. Proc Am Assoc Cancer Res 1996;37:180.
35. Gandhi V, Kisor DF, Rodriguez CO Jr., Mitchell BS, Kurtzberg J, Keating MJ, et al. Pharmacokinetics of arabinosylguanine (ara-G) and its triphosphate (araGTP) during a phase I trial of compound GW506U in refractory hematologic malignancies: correlation with response [abstract]. Blood 1996; 88(Suppl 1):670a.
36. Kurtzberg J, Keating M, Moore JO, Gandhi V, Blaney S, Gold S, et al. 2-Amino-9-B-D-arabinosyl-6-methoxy-9H-guanine (GW506U; compound 506U) is highly active in patients with T-cell malignancies: results of a phase I trial in pediatric and adult patients with refractory hematological malignancies [abstract]. Blood 1996;88(Suppl 1):669a.
37. Lambe CU, Averett DR, Paff MT, Reardon JE, Wilson JG, Krenitsky TA. 2-amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res 1995;55:3352-6.
38. Plunkett W, Hug V, Keating M, Chubb S. Quantitation of 1 -β-D-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-D-arabinofuranosylcytosine therapy. Cancer Res 1980;40:588-91.
39. Gandhi V, Danhauser L, Plunkett W. Separation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate in human leukemia cells by high-pressure liquid chromatography. J Chromatogr 1987;413:293-9.
40. Rodriguez CO Jr., Legha JK, Estey E, Keating MJ, Gandhi V. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphate in primary human leukemia cells. Clin Cancer Res 1997; 3:2107-13.